Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM™ (Antibody Recruiting Molecule) Platform, in Combination with NK Cell Therapy for the Treatment of Multiple MyelomaPRNewsWire • 10/27/21
Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive TreatmentPRNewsWire • 10/05/21
Biohaven Provides Update On Phase 3 Trial And Multiple System Atrophy (MSA) ProgramPRNewsWire • 09/27/21
Biohaven Spotlights Nurtec® ODT (rimegepant), the only dual-therapy indicated for both the acute and preventive treatment of migraine, at the 2021 International Headache Society - European Headache Federation Joint CongressPRNewsWire • 09/09/21
Why Is Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 21.7% Since Last Earnings Report?Zacks Investment Research • 09/08/21
Tuesday Afternoon Analyst Upgrades and Downgrades: SmileDirectClub, Squarespace, Victoria's Secret and More24/7 Wall Street • 08/10/21
Biohaven Pharmaceutical Holding Company's (BHVN) CEO Vlad Coric on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/09/21
Biohaven Reports Second Quarter 2021 Financial Results And Recent Business DevelopmentsPRNewsWire • 08/09/21
Analysts Estimate Biohaven Pharmaceutical Holding Company Ltd. (BHVN) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 08/02/21
Biohaven's Nurtec® ODT Signs as Official Migraine Partner of Big Machine Music City Grand Prix RacePRNewsWire • 07/29/21
Biohaven to Report Second Quarter 2021 Financial Results and Recent Business Developments on August 9, 202PRNewsWire • 07/28/21
Biohaven Rallies On Preliminary Nurtec Revenue Numbers: What Investors Need To KnowBenzinga • 07/07/21
Biohaven's stock jumps 12% after saying its migraine drug had $93 million in sales in Q2Market Watch • 07/07/21
Biohaven Announces Preliminary 2Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive TreatmentPRNewsWire • 07/07/21
Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With BiohavenPRNewsWire • 06/23/21